(Q34346535)

1 August 2017

1 reference

title

An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine (English)

1 reference

1 August 2017

1 reference

Gradoni L

1

1 reference

1 August 2017

publication date

1 September 2001

1 reference

1 August 2017

published in

Veterinary Parasitology

1 reference

1 August 2017

volume

100

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

87-103

1 reference

Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

New perspectives on a subclinical form of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Leishmaniasis in Tuscany (Italy): VIII. Human population response to leishmanin in the focus of Monte Argentario (Grosseto) and epidemiological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Molecular cloning of the major surface antigen of leishmania

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The immunology of canine leishmaniosis: strong evidence for a developing disease spectrum from asymptomatic dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Double targeted gene replacement for creating null mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Early suppression of lymphoproliferative response in dogs with natural infection by Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Vaccination trial against canine visceral leishmaniasis. Phocean Veterinary Study Group on Visceral Leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

DNA vaccines: immunology, application, and optimization*

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Potential role for interleukin-10 in the immunosuppression associated with kala azar

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

T-cell response in human leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

IL-4 Rapidly Produced by Vβ4 Vα8 CD4+ T Cells Instructs Th2 Development and Susceptibility to Leishmania major in BALB/c Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Susceptibility to infectious diseases: Leishmania as a paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The strange case of Leishmania chagasi

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Leishmania infantum, the aetiological agent of American visceral leishmaniasis (AVL)?

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Expression cloning of a protective Leishmania antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63).

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The regulation of immunity to Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Acquisition of lymphokine-producing phenotype by CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Long-term protection of mice against Leishmania major with a synthetic peptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Development of a safe live Leishmania vaccine line by gene replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

Genetic vaccination against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-4017%2801%2900486-1

7 January 2021

10.1016/S0304-4017(01)00486-1

Identifiers

DOI

1 reference

1 August 2017

1 reference